Coapt Systems Launches ENDOTINE Midface Bone 4.5 for Vertical Midface Suspension; Fifth in a Series of New ENDOTINE Product Offerings.

PALO ALTO, Calif. -- Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic and reconstructive surgery markets, announced today that it has released the ENDOTINE Midface(TM) Bone 4.5 for commercial sale in the U.S. market to coincide with the annual congress of the American Society of Aesthetic and Plastic Surgeons (ASAPS) that begins in New Orleans, Louisiana this week.

"This product is the fifth in a series of new products that we will launch over the next twelve months that will enable us to build an enduring franchise in the plastic surgery market," said John Kraczkowsky, Senior Vice President, Sales and Marketing. "The ENDOTINE Midface Bone product provides our customers with another option to suspend the midface that has many advantages when compared to prior suspension techniques. This new device completes our midface product offering, now enabling surgeons to elevate the cheek in any direction from vertical to oblique."

According to the ASAPS, there were 157,000 facelifts performed in the U.S. last year, many of which involve a midface lift. The midface lift is one of the most rapidly growing segments of the facelift market as baby boomers seek a less invasive, more subtle change in their appearance.

By eliminating the need for fixation sutures which are the most commonly used devices for midface suspension, surgeons find the ENDOTINE Midface much simpler and easier to use. It is well known that while suture suspension is effective in experienced hands, it also carries with it potential challenges, such as nerve entrapment, dimpling of tissue, tissue tear-through, extended O.R. time and surgeon frustration with lack of ability to adjust placement.

According to Dr. John Zimmermann, of Napa, California, one of the first surgeons in the U.S. to implant the new device, "The Midface Bone device can be placed quickly through a lower blepharoplasty incision, and provides secure cheek elevation to restore a youthful look to the face. Patients are very satisfied with the aesthetic results of the procedure."

The ENDOTINE Midface Bone is now available throughout the U.S. Coapt plans to introduce the Midface Bone device overseas later this year.

About Coapt Systems

Coapt Systems develops, manufactures and markets a suite of bioabsorbable implants for use in soft tissue fixation based upon its patented MultiPoint Technology (MPT(TM)) platform. Founded in 2000, the company is committed to innovation in soft tissue surgery and the development of products that enable optimal aesthetic outcomes. Other ENDOTINE facial implants with FDA clearance include the Forehead, Triple, Midface-ST, and TransBleph devices.

The company is also developing products for hand tendon and scapholunate repair. Located in Palo Alto, California, Coapt Systems, Inc. is a privately held company with 45 employees.

For further information, visit www.coaptsystems.com or contact Charlotte Copeland at 650-461-7676 or [e-mail].